Business Context and Reporting Period
This Form 8-K Current Report was filed by 22nd Century Group, Inc. on September 15, 2014, with the earliest event reported on that same date. The filing details two material definitive agreements: an investment in a Canadian biotechnology firm and a private placement of equity securities.
Key Financial Metrics and Transactions
- Investment Outlay: The Company invested $700,000 in Anandia Laboratories Inc. for a 25% equity interest.
- Equity Issuance (Investment): The Company issued 150,000 shares of its Common Stock to Anandia as part of the investment consideration.
- Future Equity Obligation: The Company agreed to issue an additional $325,000 in value of Common Stock to Anandia on or before March 31, 2015.
- Capital Raise: The Company sold 3,871,767 shares of Common Stock to Crede CG III, Ltd. at $2.5828 per share, raising approximately $10 million.
- Transaction Costs: A fee of $430,000 was agreed to be paid to Chardan Capital Markets, LLC as the exclusive placement agent.
Material Changes and Agreements
The filing reports significant strategic shifts involving intellectual property and capital structure:
- Technology Acquisition: Through the Anandia investment, 22nd Century Group secured an exclusive U.S. license and worldwide co-exclusive rights to proprietary technology for cannabinoid production. This includes 23 patent applications, one of which recently received a Notice of Allowance from the U.S. Patent and Trademark Office.
- Anti-Dilution Provisions: The Investment Agreement with Anandia includes anti-dilution protections for the Company. The Securities Purchase Agreement with Crede includes a price protection clause requiring the issuance of additional shares if the Company issues equity at a lower price before December 31, 2014.
- Registration Rights: A Registration Rights Agreement was executed with Crede, requiring the Company to register the resale of the issued shares.
Outlook, Risks, and Contingencies
Management commentary is limited to the announcement of these transactions via press releases. Key contingencies and risks identified include:
- Dilution Risk: The agreement with Crede mandates the issuance of additional shares if the Company conducts future equity offerings at a price below $2.5828 per share prior to the end of 2014.
- Future Capital Commitment: The Company has a binding obligation to issue additional stock valued at $325,000 to Anandia by March 31, 2015.
- Regulatory Compliance: The Company faces penalties under the Registration Rights Agreement if the registration statement for Crede's shares is not timely filed and declared effective by the SEC.
Investor Verification Checklist
- Verify the status of the 23 patent applications and the specific scope of the "Notice of Allowance" mentioned.
- Confirm the exact number of shares to be issued for the future $325,000 obligation to Anandia based on the share price at the time of issuance.
- Monitor future equity issuances before December 31, 2014, to assess potential dilution triggers under the Crede agreement.
- Review the full text of the Investment Agreement and Securities Purchase Agreement (Exhibits 2.1 and 2.2) for omitted schedules and detailed covenants.